Results 81 to 90 of about 62,912 (312)

3D Bioprinted Human Synovium‐Cartilage Models Mimic Rheumatoid Arthritis Microenvironment and Recapitulate In Vivo Therapeutic Responses

Advanced Materials, EarlyView.
This study presents human in vitro rheumatoid arthritis models using chondrocytes recellularized type II collagen scaffold and 3D‐bioprinted Gelatin‐Matrigel hydrogels with fibroblast‐like synoviocytes, pro‐inflammatory macrophages, and protective barrier macrophages, closely recapitulating key rheumatoid arthritis pathological features.
Huiqun Zhou, Zhen Zhang, Yulei Mu, Liang Ma, Xu Hu, Bangheng Liu, Dong‐An Wang   +6 more
wiley   +1 more source

Tofacitinib‐Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek N.   +4 more
europepmc   +2 more sources

Erythematous Macular Eruption in an Older Woman [PDF]

, 2019
A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil, McLaughlin, David, Tauro, Sudhir   +2 more
core   +2 more sources

Population‐Based Multi‐Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease

Advanced Science, EarlyView.
Psoriatic disease (PsD) is a chronic skin disease, with challenges in early risk stratification and drug development. Through gene‐level causal inference framework and expression level validation, combined with longitudinal cohort study, CDSN and PRSS8 have been identified as candidate biomarkers and therapeutic targets for PsD.
Tianxing Wu, Jialiang Luo, Haoyuan Qiu, Weijie Shao, Yueyang Lu, Meixuan Luo, Zhaofeng Lin, Yan Zhang, Libo Zhang, Hong Wang, Jia Zhou, Guangfeng Ruan, Peihua Cao, Daming Zuo   +13 more
wiley   +1 more source

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial

PLoS Medicine, 2023
Background Polymyalgia rheumatica (PMR) is a common inflammatory disease in elderly persons whose mechanism of pathogenesis has not been elucidated. Glucocorticoids are the main first-line treatments but result in numerous side effects.
Xin-Mei Ma, Fan Yang, Jinzhi Wu, Bei Xu, Mengdi Jiang, Yiduo Sun, Chuanyin Sun, Ye Yu, Danyi Xu, Lanlan Xiao, Chunyun Ren, Chun-Chin Chen, Zi Ye, Junyu Liang, Jin Lin, Weiqian Chen   +15 more
semanticscholar   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Frontiers in Pharmacology
This work aimed to explore the mechanisms underlying the interaction of the active furanocoumarins in P. corylifolia on tofacitinib both in vivo and in vitro. The concentration of tofacitinib and its metabolite M8 was determined using UPLC-MS/MS.
Yu Wang, Quan Zhou, Huihui Wang, Wei Song, Jianfeng Wang, Abdullah Al Mamun, Peiwu Geng, Yunfang Zhou, Shuanghu Wang   +8 more
doaj   +1 more source

Development of a Teaching Program on The State of the Salt Ingestion Which Prevents Heatstroke and High Blood Pressure [PDF]

, 2016
In vitro enzymatic profiles for tofacitinib and PIK-294.
Dave Singh (114223), Isabel Ramis (3541751), James Pearson (554629), Jonathan Plumb (414289), Martin Lehner (3541754), Montserrat Miralpeix (2224987), Thomas Southworth (3535091), Vandana Gupta (3541757)   +7 more
core   +6 more sources

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

Therapeutic Advances in Musculoskeletal Disease, 2023
Background: Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO). Objectives: This post hoc analysis examined baseline cardiovascular (CV) disease risk and its association ...
L. Kristensen, B. Strober, Denis Poddubnyy, Ying-Ying Leung, H. Jo, K. Kwok, I. Vranic, D. Fleishaker, L. Fallon, A. Yndestad, D. Gladman   +10 more
semanticscholar   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source